Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only



| Attribute | ||
|---|---|---|
Research Summary | As you age, some of your cells turn into "zombies"—they stop working but refuse to die, and they make nearby cells sick. FOXO4-DRI is a sniper that hunts down these zombie cells and destroys them, leaving healthy cells alone. | Epithalon is an anti-aging master switch. Imagine your cells have little shoelace caps on their DNA that wear down as you get older. Epithalon rebuilds those caps, making old cells act young again. |
Studied For | Senolytics / senescent cell clearanceAging / healthspan extensionChemotherapy-induced senescence reversalPhysical fitness restoration in aging modelsHair follicle rejuvenation in agingKidney function in aging modelsLiver health in agingInflammatory burden reductionSASP (senescence-associated secretory phenotype) suppressionp53-FOXO4 interaction disruptionApoptosis induction in senescent cellsAge-related tissue dysfunctionFrailty researchLongevity extension researchcellular senescencelongevityapoptosis of damaged cellshealthspan extensionhair regrowthfrailty | Telomere elongationAnti-aging / longevityCircadian rhythm regulationAntioxidant defenseMelatonin production stimulationPineal gland restorationImmune system enhancement in agingLifespan extension modelsCancer prevention researchDNA repairNeuroendocrine system regulationOxidative stress reductionAge-related disease preventionSleep quality via melatoninSkin anti-agingRetinal cell protectionInflammatory cytokine modulationlongevityanti-agingsleep regulationlife extensioncircadian rhythmmelatonin productiontelomere lengtheningantioxidant |
Research Areas | LongevityImmuneTissue Repair | LongevityImmuneSleep & CircadianCognitive |
Best Stacked With | epithalonnad-plusss-31thymalinbac-water | nad-plusss-31thymalinpinealonmelatoninbac-water |
Overview | ||
Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
Compound Class | D-retro-inverso peptide; protease-resistant cell-penetrating senolytic | Synthetic tetrapeptide bioregulator derived from pineal gland epithalamin |
Molecular Target | FOXO4-p53 protein-protein interaction; disrupts pro-survival signaling in senescent cells, inducing selective apoptosis | Telomerase activation (TERT); pineal melatonin synthesis; antioxidant enzyme upregulation |
Aliases / AKA | FOXO4 D-Retro-InversoFOXO4-DRI peptideFOXO4 DRIFOXO4 senolyticFOXO4-p53 disruptorSenolytic peptide | EpitalonEpithalaminAla-Glu-Asp-GlyAEDG peptideEpithalon tetrapeptidePineal peptide bioregulator |
Parent Compound | FOXO4 transcription factor | Pineal extract epithalamin fragment |
Molecular Weight | 5223 Da | 390.35 Da |
Amino Acid Sequence | ~43-residue D-amino-acid retro-inverso FOXO4 analog | Ala-Glu-Asp-Gly (AEDG) |
CAS Number | not standardized | 307297-39-8 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 25 Sparse | 217 Good |
Clinical Trials | Not Listed | Not Listed |
Regulatory Status | Not approved; investigational/research chemical. | Not FDA or EMA approved; research chemical only. |
Evidence & Regulatory | ||
Half-Life | ~24-36 hours | ~10-15 minutes |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | A landmark mouse study reported selective killing of senescent cells with restored fur, kidney function, and fitness in aged and progeroid mice. No human efficacy data exist. Preclinical only. | In vitro work in human fibroblasts reported induced telomerase activity and telomere elongation. Animal data show antioxidant and antitumor signals. Human evidence is limited, old, and from a single research group, so it is preliminary. |
Side Effects Noted | No human safety data. As a p53-activating apoptosis inducer it carries theoretical off-target apoptosis and injection-site risks. | No well characterized adverse-event profile; reported well tolerated in sparse low-quality studies. Theoretical concern that telomerase upregulation could favor proliferation of malignant cells. |
Warnings | Entirely preclinical; mechanism risk is uncharacterized in humans. Research use only. | Not approved anywhere; thin, non-independent human evidence. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | sterile or bacteriostatic water | bacteriostatic or sterile water |
Storage Temp | -20C frozen, dark | -20C frozen long-term, refrigerate after reconstitution |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | D-retro-inverso design is unusually protease-resistant; can be less soluble. | Very short plasma half-life. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Single BPC-157 versus the combined BPC-157 and TB-500 blend in recovery research.
Ipamorelin alone versus the CJC-1295 and ipamorelin blend on the growth-hormone axis.
A synthetic ACTH-fragment nootropic versus a neurotrophic peptide preparation in cognitive research.
Two sleep-research compounds with distinct mechanisms.
A copper tripeptide versus an acetyl hexapeptide in cosmetic and skin research.
A senolytic peptide versus a telomerase-pathway peptide in longevity research.
Two metabolic research compounds targeting the AMPK and NNMT pathways.
A GHRH analog versus an HGH fragment in fat-metabolism research.
Two AMPK-associated mitochondrial and metabolic research compounds.
Two peptides studied for tissue protection and repair.
Two peptides studied for immune and inflammatory modulation.
Two peptide bioregulators studied in longevity and neuro research.
A glucagon/GLP-1 dual agonist versus a GIP/GLP-1 dual agonist in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.